Lung cancer: current therapies and new targeted treatments

Fred R. Hirsch(Tisch Hospital), Luis Paz‐Ares(Hospital Universitario 12 De Octubre)

The Lancet

September 2, 2016

10.1016/s0140-6736(16)30958-8

Cited by 3,341

Related Papers

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

|Journal of Thoracic Oncology|2011|4.8k

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

|New England Journal of Medicine|2009|2.4k

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

|Nature Reviews Clinical Oncology|2021|1.5k

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

|The Lancet Oncology|2016|1.2k

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

|The Lancet Oncology|2022|738